teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneous
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoporosis, Postmenopausal
Conditions
Osteoporosis, Postmenopausal
Trial Timeline
Aug 1, 2003 → Nov 1, 2004
NCT ID
NCT00542984About teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneous
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneous is a phase 3 stage product being developed by Eli Lilly for Osteoporosis, Postmenopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT00542984. Target conditions include Osteoporosis, Postmenopausal.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00542984 | Phase 3 | Completed |
| NCT00543023 | Phase 3 | Completed |
Competing Products
20 competing products in Osteoporosis, Postmenopausal